Selank: Anxiolytic & Nootropic Peptide Research Guide

Introduction: What Is Selank?

Selank — also designated TP-7 in the Russian pharmacological literature — is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences (IMG RAS) in Moscow, with foundational work conducted by Valentina Seredenin's group beginning in the late 1980s.

Selank is structurally derived from tuftsin, an endogenous tetrapeptide (Thr-Lys-Pro-Arg) generated by enzymatic cleavage of IgG heavy chains. Tuftsin has well-characterized immunostimulant activity, but its short sequence renders it metabolically unstable — it is rapidly degraded by serum enzymes. Selank extends tuftsin's sequence with the tripeptide Pro-Gly-Pro, a modification that dramatically increases plasma stability while preserving and expanding biological activity.

In Russia, Selank has been registered as a pharmaceutical agent under the brand name Selank by Peptogen Inc., and is prescribed as an anxiolytic and nootropic. This makes it unusual in the peptide research landscape: while most peptides discussed in the research community have never entered formal regulatory pathways, Selank has accumulated a genuine clinical evidence base, primarily from Russian and Eastern European research institutions.

Outside Russia, Selank remains a research compound with no regulatory approval in the United States, European Union, or most Western jurisdictions. The following review covers the preclinical and clinical research literature as it pertains to in vitro and controlled research applications.

Molecular Properties & Metabolic Stability

Understanding Selank's unique profile begins with its molecular architecture. The parent compound tuftsin (Thr-Lys-Pro-Arg) has a plasma half-life measured in minutes — it is cleaved rapidly by leucyl aminopeptidase and carboxypeptidase N in serum. This instability severely limited its pharmacological utility despite interesting biological properties.

The addition of Pro-Gly-Pro to the C-terminus accomplishes two things simultaneously:

• Steric protection: The proline-glycine-proline tripeptide creates a conformationally rigid tail that sterically obstructs enzymatic cleavage at the Arg-4 position.
• New pharmacophore: The extension Pro-Gly-Pro is itself a fragment found in endogenous extracellular matrix proteins and has been independently associated with CNS activity, possibly through interactions with enkephalin-degrading enzymes.

The result is a compound with a plasma half-life of approximately 10–15 minutes after intranasal administration in rodents — a substantial improvement over tuftsin. Some research suggests Selank fragments generated during its degradation (particularly the tetrapeptide Thr-Lys-Pro-Arg and the tripeptide Pro-Gly-Pro) may themselves be biologically active, creating what some researchers have described as a "metabolic cascade" of activity.

Mechanism of Action

Selank's mechanisms are multifactorial and not fully elucidated. Published research points to several converging pathways that together produce its anxiolytic and nootropic profile.

GABAergic Modulation

Selank's most characterized anxiolytic mechanism involves modulation of the GABAergic system — the same system targeted by benzodiazepines, but through a distinct mechanism. Research from Medvedev et al. and others indicates Selank enhances GABA-A receptor function without acting as a direct agonist at the benzodiazepine binding site. This is consistent with its anxiolytic-without-sedation profile observed in rodent behavioral models.

Critically, Selank does not appear to cause the tolerance development, dependence potential, or respiratory depression associated with classical benzodiazepines — findings that have made it of significant pharmacological interest.

BDNF Upregulation

Among Selank's most-cited and most intriguing properties is its documented ability to upregulate Brain-Derived Neurotrophic Factor (BDNF) — a key neurotrophin governing neuronal survival, synaptic plasticity, and long-term memory consolidation.

BDNF dysregulation is implicated in numerous neurological and psychiatric conditions, including major depression, anxiety disorders, and cognitive decline. Selank's ability to upregulate BDNF through a peptide-mediated mechanism — rather than pharmacological intervention — represents a mechanistically unique approach compared to existing anxiolytics.

Serotonin & Dopamine Systems

Selank has also been found to modulate monoaminergic neurotransmission. Studies by Narkevich et al. documented Selank-induced changes in serotonin turnover in the limbic system, with effects consistent with an anxiolytic profile. Dopaminergic effects have been observed in stress models, where Selank appears to attenuate stress-induced dopamine dysregulation in the prefrontal cortex.

Enkephalin System Interactions

The Pro-Gly-Pro tripeptide in Selank's sequence shows affinity for enkephalin-degrading enzymes (neprilysin, aminopeptidase N). By inhibiting enzymatic breakdown of endogenous enkephalins, Selank may increase endogenous opioid peptide availability — providing an additional anxiolytic mechanism independent of GABA receptor modulation.

Immunomodulatory Effects

As a tuftsin derivative, Selank retains immunomodulatory activity. Tuftsin's classical role involves stimulation of phagocytic activity in macrophages and monocytes. Research with Selank in rodent models shows modulation of cytokine profiles — specifically, reduction of pro-inflammatory cytokines (IL-6, TNF-α) under stress conditions and enhancement of natural killer cell activity in immunosuppressed models.

Anxiety & Stress Research

The most extensively documented pharmacological property of Selank is its anxiolytic activity. Published research spans multiple animal models of anxiety and stress, as well as a limited body of controlled clinical trials.

The clinical trial by Neznamov and Teleshova is significant in the peptide literature because it represents a controlled human comparison against an established pharmacological agent. The finding of equivalent anxiolytic efficacy with superior tolerability is the basis for Selank's registration as a pharmaceutical in Russia.

Cognitive & Nootropic Research

Independent of its anxiolytic effects, Selank has been studied for direct cognitive-enhancing (nootropic) properties. Research in rodent learning and memory models consistently reports enhancement of memory consolidation and retrieval with Selank administration.

A mechanistic connection exists between Selank's BDNF upregulation and its nootropic effects. BDNF is a major molecular mediator of long-term potentiation (LTP) in the hippocampus — the cellular correlate of memory formation. Selank's ability to acutely elevate hippocampal BDNF mRNA provides a plausible substrate for its observed memory-enhancing effects in rodent models.

Selank vs. Classic Nootropics

Selank occupies a mechanistically distinct position compared to classical nootropics like racetams or modafinil:

Immunomodulatory Research

Given Selank's structural origin in tuftsin — a known immune activator — a parallel line of research has examined its effects on immune function. This is particularly relevant given the bidirectional relationship between anxiety disorders and immune dysregulation.

The immunomodulatory dimension of Selank is relevant because chronic anxiety and stress are well-established drivers of immune dysregulation — particularly elevated IL-6 and TNF-α and depressed NK cell activity. A compound that simultaneously addresses psychological and immune components of the stress response is pharmacologically interesting, though this dual activity makes mechanistic attribution complex.

Administration Routes in Research

Selank's administration route in published studies varies by research context. The two primary routes used are intranasal and subcutaneous/intraperitoneal injection in rodent models, with intranasal administration used in the human clinical trials.

Intranasal Administration

Intranasal delivery is the predominant route in both human clinical use (in Russia) and rodent research. The nasal route provides a direct pathway to the CNS via olfactory and trigeminal nerve pathways, bypassing first-pass hepatic metabolism. Research has confirmed that Selank reaches hippocampal and cortical tissue within minutes of intranasal administration in rodents.

Subcutaneous / IP Injection

Subcutaneous and intraperitoneal routes are used in some rodent studies, particularly when comparing dose-response relationships. Published dose ranges in rodent research: 100–600 mcg/kg for behavioral outcomes, with 300 mcg/kg being the most commonly used single dose in efficacy studies.

Selank vs. Semax: Comparative Research Overview

Selank is frequently studied alongside its close analog Semax — another Russian-developed peptide from the same research institution. While both are classified as nootropic/neuroprotective peptides with regulatory approval in Russia, they have distinct primary profiles:

Some researchers have explored combining Selank and Semax to achieve both anxiolytic and stimulant nootropic effects simultaneously — a stacking approach that leverages their complementary profiles. No formal published studies on the combination exist; this represents an area of active informal research interest.

Reconstitution Protocol (Research Use)

Selank is typically supplied as a lyophilized (freeze-dried) powder and requires reconstitution before use in liquid-phase research applications. As a relatively stable heptapeptide, Selank reconstitutes readily and maintains stability in solution when stored correctly.

Materials Required

• Lyophilized Selank vial (typical research quantities: 5 mg or 10 mg)
• Bacteriostatic water (BAC water) or sterile saline (0.9% NaCl)
• Precision syringe or calibrated micropipette
• Alcohol prep swabs (70% isopropyl)
• Refrigerator storage (2–8°C) for reconstituted solution

Reconstitution Calculations

Standard research concentrations for a 5 mg vial of Selank:

Step-by-Step Protocol

1. Allow the lyophilized vial to equilibrate to room temperature (approximately 15–20 minutes). This reduces condensation risk when opening.
2. Wipe the rubber septum with an alcohol prep swab and allow to dry completely (30 seconds).
3. Draw the target volume of BAC water or sterile saline into a clean syringe.
4. Insert the needle bevel-up at the side of the rubber stopper at a shallow angle to prevent coring.
5. Direct the solvent stream toward the glass wall of the vial rather than onto the peptide powder directly. This prevents mechanical shear denaturation.
6. Do not shake. Gently swirl or roll the vial until the powder is fully dissolved. Selank typically dissolves rapidly (15–30 seconds) given its hydrophilic character.
7. The solution should be clear and colorless. Particulate matter or cloudiness indicates potential degradation — do not use.
8. Label the vial with compound, concentration, reconstitution date, and researcher ID.

Vehicle Considerations for Intranasal Research Applications

For in vitro or ex vivo research models involving intranasal administration protocols, Selank is typically dissolved in sterile saline (0.9% NaCl) rather than BAC water, as benzyl alcohol may cause mucosal irritation. Phosphate-buffered saline (PBS, pH 7.4) is also used in some cell culture and tissue-bath applications.

Storage & Stability

Selank's heptapeptide sequence is moderately stable but requires proper storage conditions to maintain integrity for research applications:

• Lyophilized powder (sealed, long-term): -20°C freezer, protected from moisture and light. Stable for 24+ months under optimal conditions.
• Lyophilized powder (short-term): 2–8°C refrigeration for up to 3–6 months if kept sealed and desiccated.
• Reconstituted solution: 2–8°C refrigerator; use within 4–6 weeks. Do not freeze reconstituted Selank — freeze-thaw cycling degrades peptide integrity.
• Light sensitivity: Moderate. Amber glass vials or foil wrapping recommended for light-sensitive storage applications.
• pH sensitivity: Selank is stable at physiological pH (6.5–7.5). Avoid extreme pH conditions.

Selank's stability profile is considered favorable relative to many research peptides — its proline-rich C-terminal extension that confers enzymatic resistance in vivo also contributes to improved stability in solution compared to many linear peptides of similar length.

Safety Profile in Published Research

Selank's safety data is more extensive than most peptides in this category, owing to its registered pharmaceutical status in Russia. Published acute toxicity studies in rodents found no lethal dose at the doses tested (up to 500x the effective anxiolytic dose), and no organ pathology was observed in subchronic administration models.

The 14-day clinical trial by Neznamov and Teleshova (2009) found no serious adverse events, no cognitive impairment (as distinguished from benzodiazepine comparators), and no emergence of dependence or withdrawal symptoms in the follow-up period. Mild adverse events reported were limited to transient nasal discomfort at the application site with intranasal use.

No published data suggests Selank interacts with standard cytochrome P450 drug-metabolizing enzymes, though formal drug interaction studies have not been published in peer-reviewed Western literature.

Related Research Areas

Researchers studying Selank's mechanisms frequently explore these complementary areas:

• Semax — The closest structural analog, sharing the Pro-Gly-Pro stabilization motif but with stimulant/nootropic rather than anxiolytic primary activity.
• Epitalon — A tetrapeptide from the same Russian research tradition with published longevity and telomerase data. See our Epitalon research guide →
• MOTS-c — A mitochondria-derived peptide with documented effects on metabolic stress resilience and cognitive function under metabolic challenge. See our MOTS-c research guide →
• GHK-Cu — A copper-binding tripeptide with documented effects on gene expression, including BDNF pathway genes. See our GHK-Cu research guide →
• BPC-157 — A pentadecapeptide with studied effects on dopaminergic and serotonergic systems relevant to anxiety modulation. See our BPC-157 research guide →

Summary

Selank (TP-7) stands apart in the peptide research landscape for several reasons: its well-defined molecular structure, its multi-mechanism pharmacology, its unusually robust (for a peptide) human clinical data from Russian pharmaceutical trials, and its dual anxiolytic/nootropic profile without the sedation and dependence liability of classical benzodiazepines.

The core mechanistic picture that emerges from the literature is a compound that simultaneously enhances GABAergic tone, upregulates BDNF in hippocampal and cortical tissue, modulates enkephalinergic pathways, and normalizes monoaminergic dysregulation under stress — a convergence of mechanisms that may explain why its clinical anxiolytic effects appear comparable to benzodiazepines in small trials while producing a starkly different tolerability profile.

Key gaps in the literature include: independent replication in Western research institutions (most data originates from Russian groups), long-term safety data beyond 14 days, and mechanistic studies using modern tools (RNA-seq, proteomics, high-resolution receptor pharmacology) that could clarify which of its multiple proposed mechanisms are most functionally significant.

For researchers investigating the neurobiological basis of anxiety, nootropic pharmacology, or BDNF modulation, Selank represents a scientifically compelling research compound with a literature base substantially richer than most peptides discussed in research communities.